Acetyl Chloine Receptor Antibody, in Visit Clinic

A positive acetylcholine receptor (AChR) antibody test usually indicates an autoimmune attack on neuromuscular junction ACh receptors, most commonly diagnosing myasthenia gravis. It explains fluctuating muscle weakness, ptosis, diplopia and fatigability. A positive result strongly supports the diagnosis but isn’t absolute—some patients are seronegative—and further evaluation (electrophysiology, chest imaging for thymoma) and treatment may follow.

Antibodies to acetylcholine receptors are characteristic of autoimmune myasthenia gravis (both generalized and ocular forms). They commonly occur in thymoma‑associated (paraneoplastic) MG and can cross the placenta causing transient neonatal myasthenia gravis. AChR‑antibody positivity defines seropositive MG and is frequently seen alongside other autoimmune diseases such as autoimmune thyroid disease and occasionally other systemic autoimmune disorders.

High AChR antibody levels indicate an autoimmune response against nicotinic acetylcholine receptors at the neuromuscular junction, most commonly diagnosing myasthenia gravis. Clinically this explains fluctuating muscle weakness, ptosis, diplopia and bulbar symptoms. Elevated AChR antibodies usually prompt electrophysiological testing, chest imaging to exclude thymoma, and treatments like anticholinesterase drugs, immunosuppression, or thymectomy.

The acetylcholine receptor (AChR) antibody test is a blood test that detects autoantibodies against muscle ACh receptors. A positive result supports diagnosis of myasthenia gravis—common in generalized MG and less so in purely ocular disease—while a negative result doesn’t exclude MG (other antibodies or electrophysiology may be needed). Results can guide treatment and prompt thymus imaging.

For AChR‑antibody–positive myasthenia gravis, start symptomatic therapy with pyridostigmine and refer to neurology for immunotherapy. Use corticosteroids for initial control, adding steroid‑sparing agents (azathioprine, mycophenolate, tacrolimus) as needed. Thymectomy is recommended for thymoma and often for eligible generalized AChR+ patients. Manage crises with IVIG or plasma exchange, monitor respiratory function, and avoid exacerbating drugs.

Diagnosis relies on clinical history and neurological exam plus objective tests: antibody blood tests (acetylcholine receptor, MuSK, LRP4), electrophysiology (single‑fiber EMG — most sensitive; repetitive nerve stimulation), and bedside tests (ice‑pack or neostigmine/edrophonium for fluctuating ptosis/weakness). Chest imaging (CT/MRI) checks for thymoma and pulmonary tests assess respiratory risk. Evaluation by a neurologist is essential.